Company Search:
Advanced Search
Sponsored Links
Eczacibasi Ilac Sanayi ve T.A.S. Company Snapshot
Eczacibasi Ilac Sanayi ve T.A.S. operates in the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Eczacibasi Ilac Sanayi ve T.A.S. with three other pharmaceutical manufacturers in Europe: Moberg Pharma AB (publ) of Sweden (2018 sales of 439.04 million Swedish Kronor [US$46.74 million] of which 40% was Kerasal Nail /Nalox), Valneva SE of France (113.04 million Euro [US$125.73 million] of which 92% was Commercialized Vaccines), and New Nordic Healthbrands AB which is based in Sweden (393.71 million Swedish Kronor [US$41.92 million] ).

Sales Analysis. Eczacibasi Ilac Sanayi ve T.A.S. reported sales of 692.09 million Turkish Liras (US$119.17 million) for the year ending December of 2018. This represents an increase of 15.8% versus 2017, when the company's sales were 597.91 million Turkish Liras. Despite this increase, sales are still well below the level achieved in 2016, when Eczacibasi Ilac Sanayi ve T.A.S. reported sales of 1.41 billion Turkish Liras.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Eczacibasi Ilac Sanayi ve T.A.S.
  Stock Performance Chart for Eczacibasi Ilac Sanayi ve T.A.S.
  Stock Data: Recent Stock Performance:
  Current Price (12/13/2019): 3.70
(Figures in Turkish Liras)
1 Week 4.2%   13 Weeks 22.1%  
4 Weeks 31.2%   52 Weeks 32.6%  
Eczacibasi Ilac Sanayi ve T.A.S. Key Data:
  Ticker: ECILC Country: Turkey
  Exchanges: IST Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Medicinals & Botanicals
  2018 Sales 692,094,000
(Year Ending Jan 2019).
Employees: 397
  Currency: Turkish Liras Market Cap: 2,535,462,000
  Fiscal Yr Ends: December Shares Outstanding: 685,260,000
  Share Type: Common Closely Held Shares: 550,140,044
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.